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Abstract
Background: In high-income, temperate countries, IgE to allergen extracts is a risk 
factor for, and mediator of, allergy-related diseases (ARDs). In the tropics, positive 
IgE tests are also prevalent, but rarely associated with ARD. Instead, IgE responses to 
ubiquitous cross-reactive carbohydrate determinants (CCDs) on plant, insect and par-
asite glycoproteins, rather than to established major allergens, are dominant. Because 
anti-CCD IgE has limited clinical relevance, it may impact ARD phenotyping and as-
sessment of contribution of atopy to ARD.
Methods: Using an allergen extract-based test, a glycan and an allergen (glyco)protein 
microarray, we mapped IgE fine specificity among Ugandan rural Schistosoma mansoni 
(Sm)-endemic communities, proximate urban communities, and importantly in asth-
matic and nonasthmatic schoolchildren.
Results: Overall, IgE sensitization to extracts was highly prevalent (43%-73%) but al-
lergen arrays indicated that this was not attributable to established major allergenic 
components of the extracts (0%-36%); instead, over 40% of all participants recog-
nized CCD-bearing components. Using glycan arrays, we dissected IgE responses 
to specific glycan moieties and found that reactivity to classical CCD epitopes (core 
β-1,2-xylose, α-1,3-fucose) was positively associated with sensitization to extracts, 
rural environment and Sm infection, but not with skin reactivity to extracts or sensiti-
zation to their major allergenic components. Interestingly, we discovered that reactiv-
ity to only a subset of core α-1,3-fucose-carrying N-glycans was inversely associated 
with asthma.
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1  | INTRODUC TION
In high-income countries, IgE to standard allergen extracts is a 
risk factor for, and mediator of, allergy-related diseases, including 
asthma, and defines “atopic” allergy-related disease phenotypes.1-3 
In tropical low-income countries (LICs), allergen extract-specific IgE 
levels are often elevated, but rarely associated with allergy-related 
disease.4 Host immune responses to common allergen sources ex-
hibit important parallels with responses to parasite, insect and other 
environmental exposures that have related molecular targets.5 For 
example, the Onchocerca volvulus tropomyosin protein is structur-
ally homologous to house dust mite (HDM) tropomyosin and can 
induce basophil histamine release.6 Some Schistosoma mansoni (Sm) 
venom allergen-like (SmVAL) proteins (with orthologues in wasps) 
and tegumental allergen-like (SmTAL) proteins have allergenic prop-
erties.7,8 Recognition of such phenomena has provided insights re-
garding epidemiological trends of allergy in the tropics.9
The role of carbohydrate cross-reactivity in epidemiology of al-
lergic sensitization and disease is less understood. Among the com-
monest sources of cross-reactivity between natural allergens and 
other environmental exposures are specific asparagine (N) linked 
glycan modifications found on some helminth, insect and plant pro-
teins (termed cross-reactive carbohydrate determinants, CCDs). The 
N-glycan trimannosyl-chitobiose core (Man3GlcNAc2) is conserved 
in eukaryotes. “Classical” CCD N-glycans expressed by invertebrate 
and plant proteins,10,11 and on antigenic surfaces and in secretomes 
of schistosome eggs12 and some nematodes,13-16 carry additional, 
nonmammalian, IgE-binding motifs: 1) β-(1,2) xylose linked to the 
first mannose of the trimannosyl component and/or 2) α-(1,3) fucose 
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Conclusions: CCD reactivity is not just an epiphenomenon of parasite exposure 
hampering specificity of allergy diagnostics; mechanistic studies should investigate 
whether specific CCD moieties identified here are implicated in the protective effect 
of certain environmental exposures against asthma.
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G R A P H I C A L  A B S T R A C T
Reactivity to crude allergen extracts and classical CCD epitope (core β-1,2-xylose, α-1,3-fucose)-modified N-glycans is positively associated 
with the rural, Schistosoma mansoni-endemic environment. However, a higher proportion of urban, compared to rural participants, recognise 
recombinant established major allergenic components. There are inverse associations between reactivity to a subset of core α-1,3-fucose-
substituted N-glycans and asthma, but not for CCD-specific IgE in general.
Abbreviation: CCD, cross-reactive carbohydrate determinant
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linked to the asparagine-linked N-acetylglucosamine (GlcNAc) of the 
glycan core.17,18 Glycoproteins carrying such N-glycans are potent 
immune determinants,10,19-22 inducing strong Th2-type responses,23 
and comprising epitopes for antibodies,24-27 including IgE.28-30 
However, the relevance of these glycan motifs in allergy-related dis-
ease is unclear. Barring a few exceptions,31-33 anti-CCD IgE seems to 
have poor biological function: individuals with specific IgE to CCDs 
lack skin and oral reactivity to the same molecules.10,29,34
In the tropics, CCDs have been reported to dominate specific 
IgE responses.4 Among Ghanaian schoolchildren, peanut-IgE-sensi-
tization assessed by ImmunoCAP® was prevalent and strongly as-
sociated with anti-CCD IgE and Schistosoma haematobium infection, 
but not clinical peanut allergy.35 The separation of anti-CCD IgE re-
sponses from clinical allergy symptoms, coupled with abundance of 
immunogenic CCDs on glycoproteins from environmental antigens 
prevalent in tropical settings (such as some schistosome antigens), 
led us to hypothesize an inverse association between anti-CCD IgE 
reactivity and clinical allergy, possibly indicative of CCD-mediated 
inhibition of allergic effector responses.
We conducted three studies in varied Ugandan settings to ob-
tain a comparative assessment of allergy-related disease prevalence 
and risk factors in rural36 and urban37 settings, and among asthmatic 
children and controls.38 These studies provide an unprecedented 
opportunity to assess anti-CCD IgE profiles, their relevance to ep-
idemiological trends of allergic sensitization and asthma, and their 
association with the rural-urban environment and Sm exposure in 
tropical LICs.
2  | METHODS
2.1 | Study design and population
The three studies comprised rural and urban cross-sectional surveys 
on allergy outcomes and a case-control study on asthma risk factors 
among schoolchildren in Uganda.
The rural survey (September 2015-August 2016) was conducted 
in Sm-endemic fishing villages of Koome islands, Lake Victoria, 
Uganda (Figure S1). It was the three-year outcome survey of the Lake 
Victoria Island Intervention Study on Worms and Allergy-related 
diseases [LaVIISWA; ISRCTN4719603139], a cluster-randomized trial 
of community-wide standard versus intensive anthelminthic treat-
ment.39,40 The urban survey (September 2016-September 2017) was 
conducted in Entebbe municipality, a lower helminth exposure, urban 
setting37 situated on northern shores of Lake Victoria (Figure S1).
The asthma study (May 2015-July 2017)38 enrolled children 
with doctor-diagnosed asthma and controls from schools in Entebbe 
and surrounding areas. All schoolchildren were screened using the 
International Study on Allergy and Asthma in Children (ISAAC) 
questionnaire.41 Children with a history of wheeze in the last year 
underwent a detailed clinical assessment by study clinicians, includ-
ing a medical and treatment history, lung function tests, and were 
assessed for asthma control using the Asthma Control Test.38,42 
Among cases, 55.5% had well-controlled asthma, 29.5% partly con-
trolled and 15% poorly controlled asthma. Only three cases had ab-
normal lung function tests. All cases were seen at one time point, 
started on the recommended treatment and were referred for ad-
ditional management.42 Children in the same class as cases, with 
no history of wheezing, were eligible as controls. A Stata program 
(College Station, Texas, USA) was used to randomly select partici-
pants from each class register such that the number of controls was 
twice the number of cases.
Recent wheeze was also assessed in the rural and urban surveys 
using ISAAC questionnaires. Other procedures were identical in all 
three studies, including assessment of skin prick test (SPT) reactiv-
ity to allergens common in our setting43: Dermatophagoides mix (D 
pteronyssinus and D farinae), Blomia tropicalis and Blattella germanica 
(ALK-Abelló; supplied by Laboratory Specialities [Pty] Ltd., South 
Africa). Visible flexural dermatitis [evaluated following Williams’ 
online manual44], and questionnaire-determined recent rhinitis and 
urticarial rash were also assessed.
2.2 | Parasitological examinations
Infection with Sm and intestinal helminths was investigated using 
the Kato-Katz technique45 conducted on one stool sample per par-
ticipant (two slides, read by different technicians). In the urban and 
rural surveys, stool was further examined for Sm, Necator americanus 
and Strongyloides stercoralis infections using PCR,46,47 and urine for 
Sm circulating cathodic antigen (CCA, Rapid Medical Diagnostics, 
South Africa).
2.3 | Measurement of allergen- and glycan-
specific IgE
The ImmunoCAP® specific IgE test [Thermo Fisher Scientific, 
Uppsala, Sweden] (hereinafter “ImmunoCAP®”) was used to meas-
ure plasma IgE levels to whole allergen extracts of house dust mite 
(D pteronyssinus, HDM), peanut (Arachis hypogaea) and German 
cockroach (B germanica), with ≥ 0.35 kU/L defining allergic sensi-
tization.48 The ImmunoCAP® method is described in this article's 
Supplementary information.
To assess IgE reactivity to established major allergenic compo-
nents of these and other extracts, the ISAC (Immuno Solid-phase 
Allergen Chip) microarray [Thermo Fisher Scientific]49-51 was used. 
The ISAC microarray comprised112 allergen components from 51 
sources. The binding assay is described in this article's Supplementary 
information. The array comprises 67 recombinant components [pro-
duced in E coli, hence nonglycosylated52]; and 45 components pu-
rified from natural extracts (denoted by prefix “n”, eg nMUXF3 for 
the glycan epitope from bromelain). Previous work has shown that 
nMUXF3 and glycoproteins from pollen (nPhl p 4, nCyn d 1, nPla a 
2, nCry j 1, nCup a 1) and food (nJug r 2) are recognized by anti-CCD 
IgE, while other natural allergens on the ISAC are not.53 Herein, 
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“CCD-bearing components” denotes ISAC components confirmed to 
carry the classical core β-1,2-xylose and/or ⍺-1,3-fucose substituted 
N-glycans. We also use the term “established major allergenic com-
ponents” to refer to specific proteins that bind IgE to their protein 
backbone and are well-recognized as the molecular drivers of aller-
genic potency, in specific allergen sources.54,55 Participants with an 
ISAC standardized unit (ISU) measurement of ≥ 0.3 were considered 
sensitized to that allergen component.56,57 Measurements were also 
reported as detectable versus undetectable (lower detection limit: 
0.06 ISU).
A noncommercial microarray of 135 chemo-enzymatically 
synthesized glycans with and without β-1,2-xylosylation and/or 
⍺-1,3-fucosylation (Figure S2) was employed to measure plasma 
anti-glycan IgE. Microarray construction procedures have been 
published.58,59 The IgE-binding assay and the microarray image 
processing procedures were adapted from previous studies27,60-62 
and are detailed in the Supplementary information. Median fluores-
cence intensities (MFIs) reported herein represent anti-glycan IgE 
concentrations, because fluorescence-labelled anti-human IgE was 
used to detect plasma IgE bound to individual glycans on the array.
Samples were also assessed for Schistosoma egg [SEA]- and adult 
worm [SWA] antigen-specific IgE, IgG and IgG4, by ELISA [described 
elsewhere63].
2.4 | Statistical analysis
Statistical analyses were done in Stata 13.1, GraphPad Prism 7.0a 
(Fay Avenue, CA, USA) and R via the RStudio interface (version 
1.1.383; Boston, USA). Initial analyses in the rural survey investigated 
the impact of trial intervention on IgE profiles using a cluster-level 
approach, as previously described.36 Differences in characteristics 
between rural and urban survey participants and between asthmatic 
and nonasthmatic children were assessed using logistic or linear re-
gression, allowing for the survey designs (clustering and weighting). 
Unadjusted analysis of differences in individual N-glycan-/ allergen-
specific IgE levels between rural and urban participants, and be-
tween asthmatics and controls was done using the Mann-Whitney U 
test, correcting for multiple testing using a Monte Carlo simulation 
approach64 with 1000 permutations, to generate empirical p values. 
For analyses comparing prevalences of ISAC-determined IgE sensi-
tization between these groups, chi-squared tests (or Fisher's exact 
test, for expected cell counts < 5) were used.
Since anti-glycan IgE responses were strongly correlated, they 
were further analysed using principal component analysis (PCA). 
Data for participants from all studies were pooled and principal 
component (PC) scores generated. Unadjusted and age- and sex-ad-
justed associations between PC scores and atopic sensitization, 




Allergen- and glycan-specific IgE measurements were conducted in 
a subset of randomly selected samples per study (Figure 1). Data 
on ImmunoCAP®-determined IgE sensitization were available for 
780, 345 and 400 participants of the rural survey, urban survey and 
asthma study, respectively. For the rural survey, we present data 
combined from both anthelminthic treatment arms, because there 
was no effect of trial arm on ImmunoCAP®- or ISAC-determined IgE 
sensitization or on anti-glycan IgE reactivity (Table S1).36
F I G U R E  1   Selection of samples for the ImmunoCAP® test and the ISAC and glycan microarray assays
RURAL SURVEY
26 fishing villages in Koome sub-county
7741 eligible households
1820 households randomly selected (70 per village) 
1419 participating households
3566 participating individuals
2961 participants: plasma sample stored
Random sample: glycan 
microarray (n = 208)
780 participants randomly selected for 
ImmunoCAP® total and allergen-specific 
IgE test (approx. 30 per village)
Random sample: ISAC 
microarray (n = 126)
URBAN SURVEY
24 sub-wards in Entebbe municipality
13421 eligible households
420 households randomly selected for survey
416 participating households
1747 participating individuals
1356 participants: plasma sample stored
Random sample: glycan 
microarray (n =
345 participants randomly selected for 









1779 schoolchildren screened for eligibility as 
asthma cases or non-asthmatic controls
562 cases & 1140 controls enrolled into the study 
557 cases & 1128 controls: plasma sample stored
Random sample: glycan microarray 
(cases = 50, controls = 50)
200 cases & 200 controls randomly 
selected for ImmunoCAP® total and 
allergen-specific IgE test 
ISAC microarray 
(cases = 50, controls = 50)
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TA B L E  1   Characteristics of study participants
Characteristics
Rural survey Urban survey
Pb 
Case-control study on asthma in 
schoolchildren n/N (%)
Pn/N (%)a  n/N (%)a  Nonasthmatics Asthmatics
Socio-demographic
Age in years, median 
(IQR)
28 (21, 36) 22 (10, 32) .001 10 (8, 13) 11 (10, 14) .017
Male sex 377/780 (46.4) 97/345 (28.1) <.001 94/200 (46.7) 92/200 (46.0) .841
Allergy-related outcomes
Skin prick test reactivity
Any 164/780 (21.3) 72/336 (21.4) .955 60/198 (30.3) 105/198 (53.0) <.001
Dermatophagoides mix 87/780 (10.0) 61/336 (18.2) .003 47/198 (23.7) 91/198 (45.9) <.001
Blomia tropicalis 54/780 (6.8) 41/336 (12.2) .025 45/198 (22.7) 90/198 (45.4) <.001
Blattella germanica 98/780 (13.9) 45/337 (13.4) .811 32/198 (16.2) 48/198 (24.2) .046
asIgE sensitization (≥0.35 kU/L, ImmunoCAP)
Any 437/780 (55.1) 148/345 (42.9) .007 108/200 (54.0) 145/199 (72.9) <.001
D pteronyssinus 264/780 (33.2) 104/345 (30.1) .421 72/200 (36.0) 117/200 (58.5) <.001
Blattella germanica 393/780 (49.8) 118/345 (34.2) <.001 90/200 (45.0) 112/199 (56.3) .025
Arachis hypogaea 114/780 (14.9) 41/345 (11.9) .266 24/200 (12.0) 39/200 (19.5) .041
asIgE concentration (kU/L, ImmunoCAP), median (IQR)
D pteronyssinus 0.2 (0.0, 0.6) 0.1 (0.0, 0.7) .229 (0.0, 1.9) 1.0 (0.1, 37.5) <.001
Blattella germanica 0.4 (0.1, 1.5) 0.1 (0.0, 0.6) .949 0.3 (0.1, 1.1) 0.6 (0.1, 2.9) <.001
Arachis hypogaea 0.1 (0.0, 0.2) 0.0 (0.0, 0.1) .877 0.1 (0.0, 0.2) 0.1 (0.0, 0.2) .101
Total IgE (kU/L, 
ImmunoCAP), median 
(IQR)
672 (250, 1942) 159 (57, 523) <.001 279 (98, 648) 487 (115, 1248) .018
Wheeze in last 12 mo, 
age < 5 y
1/58 (0.9) 2/37 (5.4) .188
Wheeze in last 12 mo, 
age ≥ 5 y
24/716 (2.9) 5/272 (1.8) .308 0/200 (0.0) 200/200 (100.0)
Visible flexural 
dermatitis
4/780 (0.5) 3/345 (0.9) .462 3/199 (1.5) 13/198 (6.6) .019
Rhinitis in last 12 mo 34/774 (4.2) 11/309 (3.6) .700 11/199 (5.5) 43/198 (21.7) <.001
Urticaria in last 12 mo 98/773 (12.4) 11/309 (3.6) <.001 5/199 (2.5) 6/198 (3.0) .754
Helminth infections
S mansoni (KK) 187/679 (29.5) 14/284 (4.9) <.001 8/194 (4.1) 12/184 (6.5) .302
S mansoni intensity (KK)
Uninfected 492/679 (70.5) 270/284 (95.1) 186/194 (95.9) 172/184 (93.5)
Low 94/679 (14.7) 7/284 (2.5) 4/194 (2.1) 7/184 (3.8)
Moderate 53/679 (8.9) 4/284 (1.4) 3/194 (1.5) 3/184 (1.6)
Heavy 40/679 (5.8) 3/284 (1.1) <.001 1/194 (0.5) 2/184 (1.1) .328
S mansoni (urine CCA)c  590/724 (82.4) 108/309 (34.9) <.001
S mansoni (PCR)c  310/679 (47.5) 43/282 (15.3) <.001
A lumbricoides (KK) 2/679 (0.2) 0/284 (0) 0/194 (0) 1/184 (0.5)
T trichiura (KK) 44/679 (6.2) 4/284 (1.4) .002 4/194 (2.1) 2/184 (1.1) .456
N americanus (PCR) 72/679 (9.9) 12/282 (4.3) .016 3/194 (1.6)d  2/184 (1.1)d  .697
S stercoralis (PCR)c  58/679 (7.5) 4/282 (1.4) .001
Schistosoma-specific antibody levels (μg/mL), median (IQR)
(Continues)
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Table 1 shows participants’ characteristics. Rural participants 
were on average older than urban participants (P = .001) and more 
likely to be male. SPT reactivity to Dermatophagoides mix (P = .003) 
and B tropicalis (P = .025) was higher among urban participants, while 
total IgE (P < .001) and allergen extract-specific IgE sensitization 
(ImmunoCAP® concentration ≥ 0.35 kU/L), particularly to cockroach 
(P < .001), was higher among rural participants. Urticarial rash was 
more common in rural participants (P < .001), while wheeze, rhinitis 
and dermatitis were rare in both settings. Rural, compared to urban 
participants, was more frequently infected with Sm (P < .001), T trichi-
ura (P = .002), hookworm (P = .016) and S stercoralis (P = .001) and 
had higher median levels of SEA- and SWA-specific IgE, IgG and IgG4 
(P < .001). Adjusting for age and sex did not impact these differences.
Asthmatics, compared to nonasthmatic controls, had higher 
prevalence of SPT reactivity, ImmunoCAP® IgE sensitization, derma-
titis and rhinitis, and higher total IgE levels (Table 1). ImmunoCAP® 
IgE sensitization was linked to exposure-related asthma symptoms. 
For example, of the children who reported dust as a trigger for their 
asthma symptoms, 65.6% were sensitized (IgE ≥ 0.35 kU/L) to D pter-
onyssinus, compared to 46.7% who did not report dust as a trigger 
(P = .009). This difference was not statistically significant for B ger-
manica and A hypogaea-specific IgE sensitization.
Prevalence of helminth infections in the asthma study was low, 
but concentrations of SEA- and SWA-specific antibodies were mod-
erate, and similar between asthmatics and nonasthmatics (Table 1).
3.2 | Overall responses to structures on the 
ISAC and N-glycan microarray
Figure S3 shows prevalence of sensitization (IgE ≥ 0.3 ISU) to aller-
gen components on the ISAC microarray. Among rural participants, 
sensitization to components on the array was dominated by reac-
tivity to natural components bearing classical CCDs and to insect 
venom proteins (rPol d 5, rVes v 5, rApi m 1). Among urban partici-
pants and nonasthmatics, sensitization patterns were more varied: 
natural and/or recombinant HDM, venom, food and CCD-bearing 
components contributed most to sensitization. However, sensitiza-
tion among asthmatics was dominated by reactivity to major recom-
binant and natural HDM allergens.
Figure S4 shows average MFIs for structures on the glycan mi-
croarray. Although the highest responses were raised predominantly 
against core β-1,2-xylose and/or α-1,3-fucose substituted N-glycans 
in all three studies, responses to other carbohydrate structural el-
ements represented in the array, such as tri-mannose (G99), fuco-
sylated GlcNAc (G111) and galactose-alpha-1,3-galactose (α-1,3-gal) 
[G112, G113], were also as high.
3.3 | Sensitization to allergen extracts does not 
reflect sensitization to their established major 
allergenic components, except among asthmatics
In all study settings, sensitization to HDM, German cockroach and 
peanut extracts (ImmunoCAP® IgE ≥ 0.35 kU/L) was high (Table 1). 
Fifty five per cent and 43% of rural and urban participants and 
73% and 54% of asthmatic schoolchildren and their controls, re-
spectively, were sensitized to at least one of the three extracts. 
Prevalence of SPT reactivity to each extract was lower than prev-
alence of IgE sensitization to the extracts of the same allergens 
(Table 1). The majority of SPT reactive individuals (88% rural, 90% 
urban, 95% asthmatic and 93% nonasthmatic controls) were also 
IgE-sensitized to at least one of the three extracts on ImmunoCAP 
(data not shown).
Characteristics
Rural survey Urban survey
Pb 
Case-control study on asthma in 
schoolchildren n/N (%)
Pn/N (%)a  n/N (%)a  Nonasthmatics Asthmatics
SEA-specific IgE 4.6 (3.1, 6.6) 2.6 (1.7, 4.4) <.001 2.4 (1.5, 4.0) 2.4 (1.7, 3.9) .566
SWA-specific IgE 4.9 (3.0, 6.7) 2.3 (1.5, 3.4) <.001 1.9 (1.3, 3.4) 2.0 (1.5, 3.3) .914
SEA-specific IgG4 282 (70, 839) 27 (0, 90) <.001 27 (0, 77) 26 (0, 68) .255
SWA-specific IgG4 109 (52, 275) 39 (18, 65) <.001 38 (22, 64) 39 (22, 60) .871
SEA-specific IgG 1975 (1061, 3098) 739 (599, 1476) <.001 736 (602, 1318) 693 (593, 1117) .686
SWA-specific IgG 1499 (999, 2140) 791 (612, 1200) <.001 825 (644, 1130) 737 (615, 1061) .495
Note: Table shows characteristics for individuals with data on ImmunoCAP®-determined IgE sensitization. Probability values are shown for 
differences in characteristics between rural and urban survey participants and between asthmatic schoolchildren and nonasthmatic controls.
Abbreviations: asIgE, allergen-specific IgE; CCA, circulating cathodic antigen; IQR, interquartile range; KK, Kato-Katz; PCR, polymerase chain 
reaction; SEA, Schistosoma egg antigen; SWA, Schistosoma adult worm antigen.
aPercentages were adjusted for survey design. Percentages/medians that were significantly higher in one group compared to the other (P ≤ .05) are 
highlighted in bold. Adjusting for age and sex had little impact on these differences. 
bP values obtained from survey design-based logistic or linear regression. 
cInformation not collected in the asthma case-control study. 
dNecator americanus infection detected by Kato-Katz in the asthma case-control study. 
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However, ISAC microarray showed that sensitization to both nat-
ural (non-CCD-bearing) and recombinant forms of established major 
allergenic components of these extracts was very low among rural 
and urban survey participants, and among nonasthmatic schoolchil-
dren (Figure 2): 0%-3% (rural), 0%-10% (urban) and 0%-12% (nonas-
thmatics) of tested participants were sensitized (IgE ≥ 0.30 ISU) to 
HDM, cockroach and peanut components on ISAC. The picture was 
strikingly different among asthmatics: 18%-36% were sensitized to 
HDM allergens (42% to at least one) and 0%-10% to cockroach, but 
none to peanut components.
3.4 | Reactivity to CCDs dominates ISAC-
determined IgE profiles
Despite the low prevalence of ISAC-determined IgE sensitization to 
major natural and recombinant components of common allergens in 
our study settings, many participants mounted responses to compo-
nents bearing classical CCDs (Figure 3A and B). A higher proportion 
of rural, compared to urban participants, recognized CCDs (Table S2 
and Figure 3A). However, this was statistically significant only for 
the CCD-bearing components nPhl p 4 and nCry j 1. Conversely, a 
higher proportion of urban, compared to rural participants, recog-
nized recombinant established major allergens of HDM (Table S2 
and Figure 2A), the food components rApi g 1 and rMal d 1 and the 
cat allergen rFel d 4 (Table S2).
Although reactivity to HDM components was higher among 
asthmatics compared to controls, reactivity to components bearing 
classical CCDs and most other allergen components on the array was 
similar between the two groups (Figure 2 and Table S2).
Many participants also mounted responses to venom proteins 
(Figure S5). This may represent insect venom sensitization; however, 
higher reactivity was observed among rural compared to urban par-
ticipants (Table S2 and Figure S5) and among Sm infected compared 
F I G U R E  2   IgE reactivity to allergen extracts and their major allergenic components. ImmunoCAP®-determined IgE sensitization to HDM, 
German cockroach and peanut extracts and ISAC-determined IgE sensitization to the major allergenic components in these extracts. Natural 
and recombinant allergens on the ISAC array are denoted by the prefixes (n) and (r), respectively, on the allergen name. Figure shows data 
points from individuals with detectable IgE levels. Cut-offs of 0.35 kU/L and 0.30 ISU are shown to define the levels of ImmunoCAP® and 
ISAC responses, respectively, that are important for clinical diagnosis of allergic sensitization. The Mann-Whitney U test was conducted 
within the framework of a Monte Carlo simulation algorithm based on 1000 permutations (in order to adjust for multiple testing), to assess 
differences between rural and urban individuals (panels A, B and C), and between asthmatics and their controls (panels D, E and F): *P < .05; 
**P < .01; ***P < .001. HDM, house dust mite; ISAC, Immuno Solid-phase Allergen Chip; ISU, ISAC standardized units
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to uninfected participants (Table S3), possibly reflecting sensitiza-
tion to Venom-Allergen-Like (VAL) proteins expressed by schisto-
somes65 and other helminths.66,67
3.5 | Reactivity to core β-1,2-xylose/α-1,3-fucose 
is positively associated with Sm infection and 
sensitization to allergen extracts, but not sensitization 
to their established major allergenic components
Cross-reactive carbohydrate determinants expressed by several in-
sect and plant glycoproteins, and by some nematodes and trematodes 
(such as schistosomes), are typified by presence of α-1,3-linked core 
fucose and β-1,2-linked core xylose motifs.11,18 We combined the 
three studies and further explored associations between CCD-specific 
IgE and Sm infection and atopic sensitization using microarray binding 
studies of core β-1,2-xylose and α-1,3-fucose substituted N-glycans.
Responses to individual core substituted N-glycans were 
strongly correlated and were combined using PCA. Figure 4A 
shows scatterplots of PC1 and PC2 loadings (all participants). 
PC1 was characterized by responses to core β-1,2-xylose and/
or α-1,3-fucose substituted N-glycans while PC2 was character-
ized by responses to nonxylosylated and nonfucosylated glycans. 
There were positive associations between PC1 scores and (a) Sm 
infection (Figure 4B) [but not other helminths, data not shown], (b) 
the rural environment (Figure 4C), (c) HDM, cockroach and peanut 
extract-sensitization (on ImmunoCAP®) and (d) CCD sensitization 
[on ISAC] (Figure 4D-G). However, no associations were observed 
between PC1 scores and sensitization to any of the major natural 
and recombinant HDM, cockroach and peanut components on 
ISAC (Figure 4D-F).
3.6 | Inverse associations between reactivity to 
a subset of core α-1,3-fucosylated N-glycans and 
asthma, but not for CCD-specific IgE in general
No associations were observed between glycan microarray-
assessed IgE response PC scores and asthma or SPT reactivity 
(Figure 4H-I). Assessment of associations between asthma and re-
sponses to individual glycans on the array showed that asthmatics, 
compared to controls, mounted significantly lower responses to 
N-glycans carrying core α-1,3-fucose only or in combination with 
α-1,6-fucose, but not to any other structures on the array (Figure 5).
We did not group asthma cases into “allergic” and “nonallergic” 
based on ImmunoCAP® IgE sensitization, as our data showed that 
IgE to allergen extracts reflected sensitization to environmental 
exposures such as CCDs, and could not accurately define allergic 
asthma. However, we grouped asthma cases based on SPT reactivity 
to at least one allergen extract, to assess associations with responses 
to N-glycans carrying core α-1,3-fucose (Figure S6A). Compared 
to nonasthmatic controls, both “allergic” (SPT+) and “nonallergic” 
(SPT−) asthmatics mounted lower responses to core α-1,3-fucose 
substituted N-glycans. There were no differences in responses be-
tween SPT- and SPT + asthma cases. Similar results were observed 
when we based on sensitization to at least one recombinant allergen 
component on the ISAC microarray to group asthma cases into “al-
lergic” (IgE ≥ 0.3 ISU) and “nonallergic” (IgE < 0.3 ISU) [Figure S6B].
F I G U R E  3   ISAC microarray-determined IgE reactivity to components carrying classical CCDs. Natural and recombinant allergens are 
denoted by the prefixes (n) and (r), respectively, on the allergen name. Figure shows data points from individuals with detectable IgE levels. 
Cut-offs of 0.30 ISU are shown to define the level of ISAC-determined IgE responses that is important for clinical diagnosis of allergic 
sensitization. The Mann-Whitney U test was conducted within the framework of a Monte Carlo simulation algorithm based on 1000 
permutations (in order to adjust for multiple testing), to assess differences between rural and urban individuals, and between asthmatics and 
their controls: *P < .05; **P < .01; ***P < .001. ISU, ISAC standardized units; CCD, cross-reactive carbohydrate determinant
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F I G U R E  4   Associations between anti-glycan IgE responses and atopic sensitization and asthma. Figure shows data combined from all 
three studies. Panel (A) shows a scatterplot of first (PC1) and second factor (PC2) loadings derived from principal component analysis of IgE 
responses to 135 synthetic N-glycans. Box-and-whisker plots show associations between PC scores and (B) S. mansoni infection [Kato-Katz 
and/or PCR, infected n = 88; uninfected n = 154], (C) setting [rural n = 208; urban n = 62], (D) IgE sensitization (ImmunoCAP® IgE ≥ 0.35 
kU/L) to crude D. pteronyssinus extract [sensitized n = 145; nonsensitized n = 224] and sensitization (IgE ≥ 0.3 ISU) to any of the dust mite 
components on the ISAC array [sensitized n = 47; nonsensitized n = 239], (E) IgE sensitization to crude German cockroach extract [sensitized 
n = 167; nonsensitized n = 201] and to any of the German cockroach components on the ISAC array [sensitized n = 11; nonsensitized 
n = 275], (F) IgE sensitization to crude peanut (A. hypogaea) extract [sensitized n = 55; nonsensitized n = 314] and to any of the peanut 
components on the ISAC array [sensitized n = 2; nonsensitized n = 284], (G) IgE sensitization (IgE ≥ 0.30 ISU) to any of the components 
bearing classical CCDs [sensitized n = 47; nonsensitized n = 239], on the ISAC array, (H) SPT reactivity to any of Dermatophagoides 
mix, German cockroach or Blomia tropicalis [SPT + n=125; SPT- n = 241] and (I) asthma status (asthmatic n = 50; nonasthmatic n = 50). 
Horizontal lines in the plots represent medians and boxes denote interquartile ranges (IQR). Whiskers were drawn using the Tukey method 
(1.5 times IQR). Individual points represent outliers (>1.5 times IQR away from median). Associations between PC scores and the various 
comparison groups were assessed using linear regression analysis in Stata 13.1. Age- and sex-adjusted P values are shown. PC1, principal 
component 1; PC2, principal component 2; Sm, S. mansoni infection determined by Kato-Katz and/or PCR; ISAC, Immuno Solid-phase 
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4  | DISCUSSION
We conducted an assessment of associations between IgE responses 
at (sub-)molecular level and allergy outcomes among Ugandan rural 
and urban individuals, and asthmatic schoolchildren and their con-
trols. We found that among rural, urban and nonasthmatic partici-
pants, sensitization to extracts from common environmental allergens 
did not reflect sensitization to their established major allergenic com-
ponents; rather, many participants recognized CCDs. By contrast, a 
high proportion of asthmatics were sensitized to both HDM extract 
and its major components, lending substantial support to increas-
ing evidence that much asthma in tropical LICs is atopic, contrary to 
earlier perception.68,69 Detailed assessment of IgE reactivity to core 
β-1,2-xylose and/or α-1,3-fucose (well-known, nonmammalian, “clas-
sical” CCDs) using a synthetic glycan microarray revealed strong posi-
tive associations with the rural environment and Sm infection and for 
the first time showed reactivity to a subset of core α-1,3-fucose sub-
stituted N-glycans to be negatively associated with asthma.
Positive associations between antibody reactivity to classical 
CCD epitopes and the rural environment and Sm infection among 
our urban and rural survey participants were initially reported in 
our recent publication.70 Here we present data from an allergen 
extract-based test (ImmunoCAP®) and an allergen (glyco)protein 
microarray (ISAC) to confirm these associations and to explore asso-
ciations with allergic sensitization and asthma.
Allergen extracts contain a mixture of allergenic and nonaller-
genic components,71 as well as cross-reactive protein and carbo-
hydrate components that are conserved in other environmental 
antigens such as those from schistosomes.72 This obscures the 
identity of the molecular drivers, and hence interpretation, of a 
positive response in vitro to extract-specific IgE blood immunoas-
says (or in vivo to allergen extract-based SPTs). Our results show 
that this has important implications for diagnosis of atopy, and 
phenotyping of asthma (and other allergy-related conditions) as 
“atopic”, in tropical settings and for the use of population attribut-
able fractions to assess the contribution of atopy to allergy-related 
disease in tropical LICs.
The high prevalence of sensitization to CCDs and to allergen ex-
tracts but low sensitization to established major allergenic components 
in our high-Sm-transmission rural setting is reminiscent of previous 
findings by Hamid et al among Indonesian schoolchildren from areas 
endemic for soil-transmitted helminths (STH) but not schistosomes.4 
These results imply that cross-reactive protein motifs and/or CCDs 
from environmental antigens other than schistosomes play an import-
ant role in allergy epidemiology. Exposure to STH might theoretically 
contribute; however, as discussed in our previous article on associa-
tions between helminth infections and N-glycan-reactivity,70 expres-
sion of “classical” CCD epitopes in most STH is not yet well mapped, 
with STH glycomes understudied compared to the Schistosoma gly-
come. However, absence of significant associations between anti-CCD 
F I G U R E  5   Associations between asthma and IgE reactivity to glycans. (A) Heatmap of average log2-transformed MFIs representing IgE 
reactivity to each individual glycan structure on the array, in asthmatic (n = 50) versus nonasthmatic schoolchildren (n = 50). *P < .05. (B) 
Box-and-whisker plots showing MFIs representing IgE reactivity to core α-1,3-fucosylated N-glycan structures. (C) Box-and-whisker plots 
showing MFIs representing IgE reactivity to core β-1,2-xylosylated N-glycan structures. Horizontal lines in the plots represent medians, 
and boxes denote interquartile ranges (IQR). Whiskers were drawn using the Tukey method (1.5 times IQR). Individual points represent 
outliers (> 1.5 times IQR away from median). The Mann-Whitney U test was conducted within the framework of a Monte Carlo simulation 
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IgE and infection with any STH (reported here and in our previous 
study70) opposes the notion that STH express “classical” CCDs.
There is evidence showing that cross-sensitization between 
Schistosoma antigens and peanut, pollen or insect venom allergens is 
predominantly caused by CCDs.35,73,74 It is likely that previously ob-
served positive associations between Sm and HDM extract-specific 
IgE in our rural setting40 are partially attributable to CCD sensitization. 
In the same population, prevalence of clinical allergies is low, support-
ing the hypothesis that helminths may protect against allergic effector 
responses. The role of CCDs in protection against allergy, if any, is un-
clear. Alpha-1,3-gal has been implicated in meat allergy33; however, our 
studies did not find any evidence of this, despite elevated α-1,3-gal-
specific IgE concentrations. Other than α-1,3-gal-specific IgE, carbohy-
drate-specific IgE rarely, if ever, translates into clinical allergy.10,29,34,35 
We postulated that elevated IgE responses to specific immunogenic 
glycans during chronic Sm infection might result in reduced allergic ef-
fector responses. Many native allergens occur as glycoproteins; there-
fore, prior high exposure to specific CCDs (perhaps resulting from Sm 
infection or other exposures) may prime initial and recall IgE responses 
to preferentially target-specific CCD rather than the protein epitopes 
of allergens. Indeed, rural-urban comparisons of responses to compo-
nents on the ISAC array imply that in our Sm-endemic rural setting, IgE 
may be less effectively induced against common protein allergens than 
against CCDs.
In our setting, ISAC-determined anti-CCD IgE was not inversely 
associated with SPT reactivity or asthma, and PCA of microar-
ray-determined anti-glycan IgE responses suggested no overall 
association (inverse or otherwise) between asthma and anti-gly-
can IgE. However, analysis of levels of IgE to individual glycans re-
vealed that reactivity to a subset of core α-1,3-fucose substituted 
N-glycans was lower among asthmatic schoolchildren compared to 
controls, and this was consistent for all N-glycan structural variants 
on the array bearing core α-1,3-fucose only or in combination with 
α-1,6-fucose. It is plausible that responses to specific glycans are 
not merely a smokescreen that obscures readouts for assessment 
of atopy. Mechanistic investigations in animal and human studies are 
required to investigate whether specific glycans might be involved 
in protection against asthma, or whether they merely represent sur-
rogate markers of protective environmental exposures. Current ef-
forts to reconstruct specific glycoproteins (including those carrying 
N-glycan core substitutions) in plant systems75 offer great promise 
for availability of tailored glycan epitopes for initial testing in ani-
mal models. The observed inverse associations between asthma and 
core α-1,3-fucosylated N-glycans are unlikely to represent an “epi-
phenomenon” (merely reflective of inverse Sm-asthma associations) 
since, from our data, Sm prevalence and concentrations of SEA- and 
SWA-specific antibodies were similar between asthma cases and 
their controls.
Our study had some limitations. First, it would have been valu-
able to have a comparison group of asthmatics from the rural setting, 
to ascertain the generalizability of our findings and their interpre-
tation. However, as shown in Table 1 and in our previous assess-
ments,37 the prevalence of wheeze (considered a good proxy for 
asthma in epidemiological studies76) in our rural setting was very 
low (and some of it probably nonasthma related). Second, the urban 
community had considerable exposure to light helminth infections, 
while rural participants had received three years of mass anthel-
minthic treatment at the time of the survey. Nonetheless, the two 
settings were still quite distinct with regard to helminth prevalence, 
providing an interesting sample for assessing urban-rural differences 
in fine specificities of IgE responses to allergen extracts, their major 
allergenic components and “classical” CCD motifs.
Overall, our data indicate that, in tropical LICs, IgE to allergen ex-
tracts (detected in standard ImmunoCAP® assays) reflects sensitiza-
tion to a myriad of environmental exposures (absent in high-income 
countries), such as CCDs, and does not accurately define allergy-re-
lated disease phenotypes. In fact, our findings call for studies to 
investigate whether specific CCD epitopes have a mechanistic role 
in the protective effect (against asthma) of certain environmental 
exposures.
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